S. Thorne

发表

Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.

Z. Guo, D. Bartlett, S. Thorne, 2008, Biochimica et biophysica acta.

Imaging of Oncolytic Virus Gene Expression

J. Rojas, S. Thorne, 2014 .

Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines

S. Thorne, S. Albelda, E. Moon, 2018, Oncoimmunology.

Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses

S. Thorne, P. Sampath, 2013, Oncolytic virotherapy.

Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.

R. Patt, D. Kirn, S. Thorne, 2013, Cancer research.

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.

Jiwon Kim, D. Kirn, S. Thorne, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

Targeting of Interferon-Beta to Produce a Specific, Multi-Mechanistic Oncolytic Vaccinia Virus

D. Kirn, S. Thorne, J. Bell, 2007, PLoS medicine.

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer

D. Kirn, S. Thorne, David H. Kirn, 2009, Nature Reviews Cancer.

Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters

C. Contag, S. Thorne, E. Dubikovskaya, 2008, Proceedings of the National Academy of Sciences.

Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy.

C. Contag, C. Kuo, D. Kirn, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

Strategies to achieve systemic delivery of therapeutic cells and microbes to tumors

S. Thorne, 2007, Expert opinion on biological therapy.

High‐mobility group box 1 activates caspase‐1 and promotes hepatocellular carcinoma invasiveness and metastases

M. Lotze, S. Thorne, S. Monga, 2012, Hepatology.

The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally?

D. Kirn, D. Bartlett, S. Thorne, 2005, Current gene therapy.

Potential for Enhanced Therapeutic Activity of Biological Cancer Therapies with Doxycycline Combination

S. Thorne, P. Sampath, Hui Tang, 2012, Gene Therapy.

Modulation of NKG2D-ligand Cell Surface Expression Enhances Immune Cell Therapy of Cancer

S. Thorne, P. Sampath, R. Sikorski, 2011, Journal of immunotherapy.

Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1

D. Kirn, S. Thorne, B. Huang, 2011, Gene Therapy.

Tunable pH-Responsive Polymeric Micelle for Cancer Treatment.

S. Thorne, Song Li, Peng Zhang, 2015, ACS macro letters.

IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell

Joe-Marc Chauvin, H. Zarour, V. Hornung, 2019, Cancer Immunology Research.

Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver

D. Sze, D. Kirn, S. Thorne, 2006, Cancer Gene Therapy.

First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.

D. Kirn, H. Zeh, D. Bartlett, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Immunotherapeutic Potential of Oncolytic Vaccinia Virus

S. Thorne, 2014, Front. Oncol..

Regulating cytokine function enhances safety and activity of genetic cancer therapies.

S. Thorne, W. Hou, Hannah Chen, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.

M. Gorry, D. Bartlett, S. Thorne, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.

D. Bartlett, S. Thorne, W. Hou, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity.

D. Bartlett, S. Thorne, P. Sampath, 2012, Neoplasia.

Immunotherapeutic potential of oncolytic vaccinia virus

S. Thorne, 2011, Immunologic research.

Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy.

C. Contag, S. Thorne, P. Sampath, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.

D. Kirn, S. Thorne, C. Breitbach, 2012, Current pharmaceutical biotechnology.

Oncolytic Virotherapy and the Tumor Microenvironment.

D. Bartlett, S. Thorne, Sara E Berkey, 2017, Advances in experimental medicine and biology.

Giving oncolytic vaccinia virus more BiTE.

S. Thorne, S. Albelda, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

The role of GM-CSF in enhancing immunotherapy of cancer.

S. Thorne, 2013, Immunotherapy.

Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.

G. Cheng, S. Thorne, S. Albelda, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Treating Tumors With a Vaccinia Virus Expressing IFNβ Illustrates the Complex Relationships Between Oncolytic Ability and Immunogenicity.

G. Cheng, S. Thorne, S. Albelda, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

Z. Guo, D. Bartlett, S. Thorne, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells.

D. Felsher, C. Contag, S. Thorne, 2010, Cancer Research.

Enhancing poxvirus oncolytic effects through increased spread and immune evasion.

C. Contag, D. Kirn, S. Thorne, 2008, Cancer Research.

Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects.

T. Hermiston, D. Kirn, S. Thorne, 2005, Seminars in oncology.

Synergistic interaction between oncolytic viruses augments tumor killing.

H. Atkins, J. Diallo, D. Kirn, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy.

J. Rojas, S. Thorne, W. Hou, 2016, Cancer cell.

Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy

J. Rojas, S. Thorne, W. Hou, 2015, Clinical Cancer Research.

Bioinspired Controlled Release of CCL22 Recruits Regulatory T Cells In Vivo

S. Thorne, A. Thomson, G. Raimondi, 2012, Advanced materials.

Sustained inhibition of PKCα reduces intravasation and lung seeding during mammary tumor metastasis in an in vivo mouse model

Jeewon Kim, S. Thorne, D. Mochly‐Rosen, 2010, Oncogene.

Oncolytic Viruses: Methods and Protocols

D. Kirn, S. Thorne, Ta-Chiang Liu, 1972, Nature.

Effects of Febrile Temperature on Adenoviral Infection and Replication: Implications for Viral Therapy of Cancer

L. Eng, S. Thorne, T. Reid, 2005, Journal of Virology.

Manipulating TLR Signaling Increases the Anti-tumor T Cell Response Induced by Viral Cancer Therapies

J. Rojas, S. Thorne, D. Byrd, 2016, Cell reports.

Practical Methods for Molecular In Vivo Optical Imaging

S. Thorne, Hannah Chen, 2012, Current protocols in cytometry.

Manipulating the expression of chemokine receptors enhances delivery and activity of cytokine-induced killer cells

Y. Zou, S. Thorne, W. Hou, 2014, British Journal of Cancer.

Oligoadenylate‐Synthetase‐Family Protein OASL Inhibits Activity of the DNA Sensor cGAS during DNA Virus Infection to Limit Interferon Production

N. DeLuca, S. Thorne, P. Sampath, 2019, Immunity.

Virus fuels NK cell killing of leukemia.

S. Thorne, 2016, Blood.

Adding STING to the Tale of Oncolytic Virotherapy.

S. Thorne, 2016, Trends in cancer.

Theranostic Potential of Oncolytic Vaccinia Virus

J. Rojas, S. Thorne, 2012, Theranostics.

Splenectomy Promotes Indirect Elimination of Intraocular Tumors by CD8+ T Cells That Is Associated with IFNγ- and Fas/FasL-Dependent Activation of Intratumoral Macrophages

S. Thorne, Dana M Previte, S. Harvey, 2014, Cancer Immunology Research.

Fluoromodule-based reporter/probes designed for in vivo fluorescence imaging.

M. Bruchez, A. Waggoner, J. Rojas, 2015, The Journal of clinical investigation.

CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency

S. Thorne, D. Byrd, W. Hou, 2020, Journal for ImmunoTherapy of Cancer.

New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolution

C. Contag, S. Thorne, A. Matin, 2006, Molecular Cancer Therapeutics.

Ablating CAR and integrin binding in adenovirus vectors reduces nontarget organ transduction and permits sustained bloodstream persistence following intraperitoneal administration.

D. Kirn, S. Thorne, T. Wickham, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Enhanced Killing of Primary Ovarian Cancer by Retargeting Autologous Cytokine-Induced Killer Cells with Bispecific Antibodies: A Preclinical Study

C. Contag, J. Chan, S. Thorne, 2006, Clinical Cancer Research.

Withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown

Shivendra V. Singh, S. Thorne, A. Lokshin, 2016, Breast Cancer Research and Treatment.

Is the immune response a friend or foe for viral therapy of glioma?

S. Thorne, H. Okada, 2017, Neuro-oncology.

Enhancing biological therapy through conditional regulation of protein stability

S. Thorne, 2010, Expert Reviews in Molecular Medicine.

Using in Vivo Bioluminescence Imaging to Shed Light on Cancer Biology

Steve Thorne, Christopher H. Contag, C. Contag, 2005, Proceedings of the IEEE.

A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses.

D. Kirn, N. Lemoine, S. Thorne, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10

L. Butterfield, S. Thorne, N. Vujanović, 2012, Oncoimmunology.

Consensus guidelines for the detection of immunogenic cell death

P. Vandenabeele, S. Loi, L. Zitvogel, 2014, Oncoimmunology.

CTL- vs Treg lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma

S. Thorne, Y. Zhang, S. Zhao, 2015, British Journal of Cancer.

Local production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma

Bin Zhang, S. Thorne, P. Kalinski, 2015, Oncotarget.

Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity

H. Atkins, J. Diallo, M. Burdick, 2015, Nature Medicine.

White paper on microbial anti-cancer therapy and prevention

Shibin Zhou, R. Vile, G. McFadden, 2018, Journal of Immunotherapy for Cancer.

Synergistic Antitumor Effects of Immune Cell-Viral Biotherapy

C. Contag, S. Thorne, R. Negrin, 2006, Science.

Gene Therapy and Virus-Based Cancer Vaccines

S. Thorne, B. Fielding, M. Salem, 2015 .

Dual Promoter–Controlled Oncolytic Adenovirus CG5757 Has Strong Tumor Selectivity and Significant Antitumor Efficacy in Preclinical Models

S. Thorne, P. Working, T. Reid, 2005, Clinical Cancer Research.

Variola and Monkeypox Viruses Utilize Conserved Mechanisms of Virion Motility and Release That Depend on Abl and Src Family Tyrosine Kinases

D. Kalman, W. Bornmann, S. Thorne, 2010, Journal of Virology.

Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy

S. Thorne, P. Sampath, 2015, Oncolytic virotherapy.

Oncolytic adenoviruses for cancer gene therapy.

D. Kirn, S. Thorne, Ta-Chiang Liu, 2008, Methods in molecular biology.

Vaccinia virus and oncolytic virotherapy of cancer.

D. Kirn, S. Thorne, T. Hwang, 2005, Current opinion in molecular therapeutics.

Importance of glycolysis and oxidative phosphorylation in advanced melanoma

J. Kirkwood, J. Ho, B. Van Houten, 2012, Molecular Cancer.

Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer

Steve Thorne, Gabor M. Rubanyi, I. Kuhn, 2008, PloS one.

Chemical control of protein stability and function in living mice

C. Contag, T. Wandless, S. Thorne, 2008, Nature Medicine.

Oncolytic Viruses Engineered to Enforce Leptin Expression, Reprogram Tumor-Infiltrating T Cell Metabolism, and Promote Tumor Clearance.

R. Ferris, S. Thorne, Greg M. Delgoffe, 2019, Immunity.

Replication‐Selective Viruses for the Treatment of Cancer

S. Thorne, P. Sampath, 2010 .

Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus

D. Kirn, S. Thorne, 2004, Expert opinion on biological therapy.

Alternate mechanisms of initial pattern recognition drive differential immune responses to related poxviruses.

Peter O. Krutzik, Erin F. Simonds, G. Nolan, 2010, Cell host & microbe.

Ethyl pyruvate administration inhibits hepatic tumor growth

M. Lotze, H. Zeh, S. Thorne, 2009, Journal of leukocyte biology.

Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors

H. Atkins, J. Diallo, D. Kirn, 2010, PloS one.

The Initial Phase of an Immune Response Functions to Activate Regulatory T Cells1

Peter O. Krutzik, Erin F. Simonds, G. Nolan, 2009, The Journal of Immunology.

The Initial Phase of an Immune Response

Peter O. Krutzik, Erin F. Simonds, G. Nolan, 2009 .

Oncolytic Viruses Enginee red to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance Graphical

R. Ferris, S. Thorne, Greg M. Delgoffe, 2019 .

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.

D. Kirn, D. Bartlett, S. Thorne, 2007, The Journal of clinical investigation.

Replication-selective oncolytic adenoviruses.

D. Kirn, S. Thorne, G. Halldén, 2004, Methods in molecular medicine.

In vivo inflammation imaging using a CB2R-targeted near infrared fluorescent probe.

S. Thorne, C. Anderson, W. Hou, 2015, American journal of nuclear medicine and molecular imaging.

Role of nitric oxide in Salmonella typhimurium-mediated cancer cell killing

Christopher H Contag, C. Contag, F. Schreiber, 2010, BMC Cancer.

CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy

Christopher H Contag, Jianghong Rao, C. Contag, 2009, Molecular Cancer Therapeutics.

Next-generation oncolytic vaccinia vectors.

S. Thorne, 2012, Methods in molecular biology.

Differential biodistribution of oncolytic poxvirus administered systemically in an autochthonous model of hepatocellular carcinoma

G. Vassaux, S. Thorne, J. Cany, 2011, The journal of gene medicine.

Antibody-based immunotherapy: targeting CSPG4 on human basal breast cancer stem cells.

S. Ferrone, A. Deleo, H. Lyerly, 2009 .

Molecular and Cellular Pathobiology Ampli fi cation of FRS 2 andActivation of FGFR / FRS 2 Signaling Pathway in High-Grade Liposarcoma

So, Hanlin Gao, Jinhui Wang, 2013 .

Cell Host & Microbe Alternate Mechanisms of Initial Pattern Recognition differences in cytokine production among strains

Erin F. Simonds, G. Nolan, G. Karupiah, 2010 .